Search clinical trials for: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrasti

Total 466 results

University of Tennessee Cancer Institute
Genentech, Inc.; Celgene Corporation; National Comprehensive Cancer Network

Unknown

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

Breast Cancer

United States
The Netherlands Cancer Institute

Active, not recruiting

Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer (neo-TN)

Breast Cancer

Netherlands
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States
Commissie Voor Klinisch Toegepast Onderzoek

Unknown

Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer

Lung Cancer

Netherlands
National Cancer Centre, Singapore

Terminated

Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery

Breast Cancer

Singapore
Hunan Cancer Hospital

Recruiting

Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer

Ovarian Cancer

China
M.D. Anderson Cancer Center
Lyvgen Biopharma Holdings Limited

Recruiting

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Gastric Cancer | Metastatic Uveal Melanoma | Metastatic Head and Neck Carcinoma | Metastatic Hepatocellular Carcinoma | Metastatic Ovarian Carcinoma | Metastatic Soft Tissue Sarcoma | Metastatic Esophageal | Metastatic HPV Related Solid Tumors

United States
University of Washington
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
Shanghai Henlius Biotech

Not yet recruiting

to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer

Endometrial Cancer

United States
Sanofi

Completed

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

Breast Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Norway
St. Jude Children's Research Hospital
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma

Retinoblastoma

United States
Swiss Group for Clinical Cancer Research

Completed

Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer

Ovarian Cancer

Switzerland
ImmunityBio, Inc.

Active, not recruiting

QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Non Small Cell Lung Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Surgery in Treating Children With Neuroblastoma

Neuroblastoma

United States, Canada, Puerto Rico, Australia, Netherlands, Switzerland, New Zealand
National Cancer Institute (NCI)

Recruiting

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)

Malignant Solid Neoplasm

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Advanced Endometrial Cancer | Sarcoma of Uterus

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Endometrial Cancer

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Breast Cancer

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.

Lung Cancer | Carcinoma of Unknown Primary

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Sarcoma

United States
NCIC Clinical Trials Group
Southwest Oncology Group; Cancer and Leukemia Group B; North Central Cancer Treatment...

Completed

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Breast Cancer

Canada, United States
Genelux Corporation
GOG Foundation

Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Platinum-refractory Ovarian Cancer | Primary Peritoneal Cancer | High-grade Serous Ovarian Cancer | Endometrioid Ovarian Cancer | Ovarian Clear Cell Carcinoma

United States
Medical Research Council

Unknown

Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer

Ovarian Cancer

United Kingdom
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.; Celgene Corporation

Completed

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Ohio State University Comprehensive Cancer Center
Genentech, Inc.; Celgene Corporation

Completed

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

Breast Cancer

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer

Lung Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
Hebei Medical University Fourth Hospital

Withdrawn

Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC

Triple Negative Breast Cancer

China
Xijing Hospital

Recruiting

PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
Fudan University

Recruiting

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (BCTOP-T-M01)

Triple-Negative Breast Cancer

China
University of Washington
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease

Unspecified Adult Solid Tumor, Protocol Specific
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Unknown

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

Breast Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Breast Cancer

United States
St. Louis University

Unknown

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Breast Cancer

United States
St. Louis University

Unknown

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
Baylor Research Institute

Completed

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer

Breast Cancer

United States
Leo W. Jenkins Cancer Center

Terminated

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

Breast Cancer

United States
Georgetown University

Recruiting

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (RAGE)

Non-metastatic Breast Cancer | Cancer Related Cognitive Decline

United States
Louisiana State University Health Sciences Center...

Terminated

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Breast Cancer

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)

Triple Negative Breast Neoplasms
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Stage IIIA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States, Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States

Search clinical trials for: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrasti

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations